| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Aug 10, 2020
Acquisition of OXER1 R&D Program Joined the CoVIg-19 Plasma Alliance Voluntary Delisting from Toronto Stock Exchange Net loss from continuing operations for Q2 2020 reduced by approximately 80%...
-
Aug 6, 2020
nt at Canaccord 40th Annual Growth Conference Liminal Biosciences to Present at Canaccord 40th Annual Growth Conference AUGUST 6, 2020 SHRINAL INAMDAR LAVAL, QC, and CAMBRIDGE, ENGLAND – August...
-
Jul 22, 2020
LAVAL, CANADA, and CAMBRIDGE, ENGLAND – July 22, 2020 – Liminal BioSciences Inc. (Nasdaq & TSX: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical...
-
Jul 17, 2020
LAVAL, CANADA, and CAMBRIDGE, ENGLAND – July 17, 2020 – Liminal BioSciences Inc. (Nasdaq & TSX: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical...
-
Jul 2, 2020
LAVAL, CANADA, and CAMBRIDGE, ENGLAND – July 2, 2020 – Liminal BioSciences Inc. (Nasdaq & TSX: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical...